The U.S. cannabis market continues to face dramatic policy changes at both the federal and state level, and Benesch's Cannabis insights help businesses understand what's coming next. A U.S. House subcommittee has advanced a bill barring the Department of Justice from rescheduling cannabis, directly opposing the Biden administration's push to reclassify marijuana under the Controlled Substances Act. For companies following Benesch's Cannabis guidance, this is a critical development that could reshape compliance strategies nationwide.
According to Benesch's Cannabis policy team, Congress is simultaneously targeting hemp reforms. House and Senate appropriations committees recently approved measures to redefine hemp and ban most hemp-derived THC products, including delta-8 and THCA. This move has sparked major concerns within the industry. Benesch's Cannabis lawyers warn that these changes could significantly disrupt supply chains, particularly for businesses relying on hemp-derived cannabinoids.
Benesch's Cannabis analysts point out that these delays create uncertainty for investors and operators trying to anticipate regulatory timelines. At the same time, lawmakers passed an amendment allowing VA doctors to recommend medical cannabis to veterans a breakthrough for patient access that Benesch's Cannabis policy briefs have tracked closely.
Copyright
©420 Intel